Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BAFF-neutralizing interaction of belimumab related to its therapeutic efficacy for treating systemic lupus erythematosus.

Nature communications - 23 Mar 2018

Shin Woori, Lee Hyun Tae, Lim Heejin, Lee Sang Hyung, Son Ji Young, Lee Jee Un, Yoo Ki-Young, Ryu Seong Eon, Rhie Jaejun, Lee Ju Yeon, Heo Yong-Seok

Abstract excerpt

BAFF, a member of the TNF superfamily, has been recognized as a good target for autoimmune diseases. Belimumab, an anti-BAFF monoclonal antibody, was approved by the FDA for use in treating systemic lupus erythematosus. However, the molecular basis of BAFF neutralization by belimumab remains unclear. Here our crystal structure of the BAFF-belimumab Fab complex shows the precise epitope and the BAFF-neutralizing...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amino Acid Motifs
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to B-Cell Activating Factor

Share to B-Lymphocytes

Share to Chromatography, Gel

Share to Epitopes

Share to Immunosuppressive Agents

Share to Lupus Erythematosus, Systemic

Source

Open in PubMed Open full text

Identifiers

PMID: 29572471
DOI: 10.1038/s41467-018-03620-2
PMCID: PMC5865148

Genes

TNF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BAFF-neutralizing interaction of belimumab related to its therapeutic efficacy for treating systemic lupus erythematosus.PMID 29572471Read ↗

A loop region of BAFF controls B cell survival and regulates recognition by different inhibitors.Semantic proximity Read ↗

The complexity of the BAFF TNF-family members: implications for autoimmunity.Semantic proximity Read ↗

Mutation of the BAFF furin cleavage site impairs B-cell homeostasis and antibody responses.Semantic proximity Read ↗

Comparison of soluble decoy IgG fusion proteins of BAFF-R and BCMA as antagonists for BAFF.Semantic proximity Read ↗

BAFF signaling in health and diseaseSemantic proximity Read ↗

Investigation of novel therapeutic strategies in B cell and antibody mediated diseaseSemantic proximity Read ↗

Belimumab promotes negative selection of activated autoreactive B cells in systemic lupus erythematosus patients.Semantic proximity Read ↗

Crystal structure and molecular dynamics simulations of rademikibart Fab-IL-4Rα complex reveal biochemical basis for next-generation potent IL-4Rα inhibition in type 2 allergic and inflammatory diseasesSemantic proximity Read ↗

Ligand-receptor binding revealed by the TNF family member TALL-1.Semantic proximity Read ↗

LFA-1 as a Key Regulator of Immune Function: Approaches toward the Development of LFA-1-Based TherapeuticsSemantic proximity Read ↗

Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton’s Tyrosine KinaseSemantic proximity Read ↗

The crystal structure of a proliferation-inducing ligand, APRIL.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.